drugset / Trial / NCT00884715
Pharmacokinetics, Efficacy and Safety of an Octreotide Implant in Patients With Carcinoid Syndrome
Non-randomizedParallel-groupOpen-labelTreatment
Summary
Evaluate the pharmacokinetics, safety and efficacy of an octreotide implant for the treatment of the symptoms of carcinoid syndrome.
Timeline
- Start
- 2009-07
- Primary completion
- 2011-11
- Completion
- 2011-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Octreotide | Peptide | 117 mg | Subcutaneous |
| Subject | Octreotide | Peptide | 234 mg | Subcutaneous |